↓ Skip to main content

The burden of disease in patients eligible for mentalization-based treatment (MBT): quality of life and costs

Overview of attention for article published in Health and Quality of Life Outcomes, October 2016
Altmetric Badge

Mentioned by

twitter
1 X user
facebook
1 Facebook page
reddit
1 Redditor

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
79 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The burden of disease in patients eligible for mentalization-based treatment (MBT): quality of life and costs
Published in
Health and Quality of Life Outcomes, October 2016
DOI 10.1186/s12955-016-0538-z
Pubmed ID
Authors

Elisabeth M. P. Laurenssen, Hester V. Eeren, Martijn J. Kikkert, Jaap Peen, Dieuwertje Westra, Jack J. M. Dekker, Jan J. V. Busschbach

Abstract

Mentalization-Based Treatment (MBT) is a promising, though expensive treatment for severely ill patients with Borderline Personality Disorder (BPD). A high burden of disease in terms of quality of life (QoL) and life years lost can be a reason to prioritize mental health interventions, and specifically for BPD patients. Moreover, when the societal costs of the illness are high, spending resources on high treatment costs would be more easily legitimized. Therefore, the purpose of this study was to calculate the burden of disease of BPD patients eligible for MBT. The 403 patients included in this study were recruited from two mental health care institutes in the Netherlands. All patients were eligible for MBT. Burden of disease consisted of QoL, measured with the EuroQol EQ-5D-3L, and costs, calculated using the Trimbos and Institute for Medical Technology Assessment Questionnaire for Costs Associated with Psychiatric Illness. The mean QoL index score was .48. The mean total costs in the year prior to treatment were €16,879 per patient, of which 21 % consisted of productivity costs. The burden of disease in BPD patients eligible for MBT is high, which makes it more likely that society is willing to invest in treatment for these patients. However, this finding should not be interpreted as a license to unlimitedly use resources to reimburse treatment for severe BPD patients, as these findings do not provide any information on the effectiveness of MBT or other available treatment programs for BPD. The effectiveness of available treatments should be evident by studies on the effectiveness of the treatment itself and by comparing the effectiveness of these treatments to treatment as usual and to other treatment options for BPD patients. The data on this paper came from two trials: NTR2175 and NTR2292 .

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 79 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 19%
Student > Master 12 15%
Student > Ph. D. Student 6 8%
Researcher 5 6%
Student > Doctoral Student 4 5%
Other 11 14%
Unknown 26 33%
Readers by discipline Count As %
Psychology 34 43%
Nursing and Health Professions 7 9%
Medicine and Dentistry 4 5%
Environmental Science 1 1%
Business, Management and Accounting 1 1%
Other 6 8%
Unknown 26 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2016.
All research outputs
#17,820,151
of 22,893,031 outputs
Outputs from Health and Quality of Life Outcomes
#1,469
of 2,160 outputs
Outputs of similar age
#228,377
of 319,855 outputs
Outputs of similar age from Health and Quality of Life Outcomes
#21
of 40 outputs
Altmetric has tracked 22,893,031 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,160 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,855 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.